A mother's love drives her to pursue experimental treatment as two of her four children battle a rare genetic disease that ...

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.

By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease progression and showed sustained benefit in patients' ability to control and ...

In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid screening tool to help identify individuals with Duchenne muscular ...

Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” ・Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

The Enquirer and United Way of Greater Cincinnati have joined forces for the 39th year to help families in need with the Wish List program. After wishes are granted, remaining funds assist people with ...

Capricor Therapeutics reported positive data from its phase three study of its Deramiocel therapy to treat Duchenne muscular dystrophy. The company said the study met the primary endpoint and the key ...

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to ...

The U.S. Food and Drug Administration is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after two teenagers died from liver failure linked to the medication. The ...